Hectorol

Hectorol is a brand name of doxercalciferol, approved by the FDA in the following formulation(s):

HECTOROL (doxercalciferol - capsule; oral)

• 
  Manufacturer: GENZYME CORP
  
  Approval date: June 9, 1999
  
  Strength(s): 2.5MCG ^[RLD]


• 
  Manufacturer: GENZYME CORP
  
  Approval date: April 23, 2004
  
  Strength(s): 0.5MCG ^[AB]


• 
  Manufacturer: GENZYME CORP
  
  Approval date: July 13, 2009
  
  Strength(s): 1MCG
  

HECTOROL (doxercalciferol - injectable; injection)

• 
  Manufacturer: GENZYME CORP
  
  Approval date: April 6, 2000
  
  Strength(s): 2MCG/ML (2MCG/ML), 4MCG/2ML (2MCG/ML) ^[RLD]

Has a generic version of Hectorol been approved?

A generic version of Hectorol has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Hectorol and have been approved by the FDA:

doxercalciferol capsule; oral

• 
  Manufacturer: ROXANE
  
  Approval date: September 23, 2011
  
  Strength(s): 0.5MCG ^[AB]

Note: No generic formulation of the following product is available.

• doxercalciferol - injectable; injection

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Hectorol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for treating and preventing secondary hyperparathyroidism
  Patent 5,602,116
  Issued: February 11, 1997
  Inventor(s): Knutson; Joyce C. & Bishop; Charles W. & Mazess; Richard B.
  Assignee(s): Bone Care International, Inc.
  A method for preventing loss of bone mass or bone mineral content in a human being suffering from secondary hyperparathyroidism by administering a sufficient amount of 1.alpha.-OH vitamin D.sub.2, 1.alpha.,24(S)-(OH).sub.2 vitamin D.sub.2, 1.alpha.-OH vitamin D.sub.4 or 1.alpha.,24(R)-(OH).sub.2 vitamin D.sub.4.
  
  Patent expiration dates:
  
  
  • February 11, 2014
    
    ✓ 
    Patent use: TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
  
  
  
  • February 11, 2014
    
    ✓ 
    Patent use: METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
  
  
  
  • February 11, 2014
    
    ✓ 
    Patent use: REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
  
  



• 
  Stabilized hydroxyvitamin D
  Patent 6,903,083
  Issued: June 7, 2005
  Inventor(s): Knutson; Joyce C. & Mazess; Richard B. & Bishop; Charles W.
  Assignee(s): Bone Care International, Inc.
  The invention provides a stabilized 1α-hydroxyvitamin D (“SHVD”) which is particularly well suited for pharmaceutical formulations.
  
  Patent expiration dates:
  
  
  • July 18, 2021
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
    ✓ 
    Sponsor has requested patent be delisted
  
  



• 
  Formulation for lipophilic agents
  Patent 7,148,211
  Issued: December 12, 2006
  Inventor(s): Mazess; Richard B. & Driscoll; Jeffrey W. & Goldensoph; Creighton Reed & LeVan; Leon W.
  Assignee(s): Genzyme Corporation
  The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same.
  
  Patent expiration dates:
  
  
  • September 14, 2023
    
    ✓ 
    Drug product
  
  

See also...

• Hectorol Consumer Information (Wolters Kluwer)
• Hectorol Capsules Consumer Information (Wolters Kluwer)
• Hectorol Consumer Information (Cerner Multum)
• Hectorol AHFS DI Monographs (ASHP)
• Doxercalciferol Consumer Information (Wolters Kluwer)
• Doxercalciferol Capsules Consumer Information (Wolters Kluwer)
• Doxercalciferol Consumer Information (Cerner Multum)
• Doxercalciferol AHFS DI Monographs (ASHP)